Know Cancer

or
forgot password

Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen (ProDLBCL)


N/A
18 Years
N/A
Not Enrolling
Both
B-Cell Lymphomas

Thank you

Trial Information

Prognosis Of Patients With Aggressive B-Cell Lymphoma, Treated With Rituximab+Anthracycline Regimen (ProDLBCL)


Inclusion Criteria:



1. Histologically confirmed newly diagnosed aggressive B-cell lymphoma according to the
current World Health Organisation Classification, from 2001 to 2007.

2. Any stage of disease.

3. Treatment with R-CHOP or R-CHOP like regimens (+/- transplant).

4. Age at least 18 years.

5. Availability of tissue biopsy at diagnosis for a possible centralized revision.

6. Availability of data on clinical involvement, laboratory, treatment and follow up.

Exclusion Criteria:

- None

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Retrospective

Principal Investigator

Massimo Federico, MD

Investigator Role:

Study Director

Investigator Affiliation:

Oncologia II Azienda Ospedaliera Universitaria di Modena

Authority:

Italy: The Italian Medicines Agency

Study ID:

IIL_ProDLBCL

NCT ID:

NCT01478269

Start Date:

May 2009

Completion Date:

May 2011

Related Keywords:

  • B-Cell Lymphomas
  • Aggressive B-cell lymphoma
  • R-CHOP
  • Aggression
  • Lymphoma
  • Lymphoma, B-Cell

Name

Location